Brief: Xbrane Biopharma Q4 EBITDA Loss SEK 50.7 Mln
17/02/2023 07:21
Feb 17 (Reuters) - Xbrane Biopharma AB XBRANE.ST :
* Q4 REVENUE AMOUNTED TO SEK 17.3 M (2.8)
* Q4 EBITDA AMOUNTED TO SEK -50.7 M (-28.2)
* Q4 LOSS FOR PERIOD WAS SEK -60.7 M (-32.5)
* BOARD OF DIRECTORS PROPOSES THAT NO DIVIDEND BE PAID FOR
FINANCIAL YEAR 2022
Source text: https://mfn.se/a/xbrane-biopharma/the-approval-of-ximluci-r-in-europe-positions-xbrane-as-a-leading-global-biosimilar-developer
Further company coverage: XBRANE.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))